EUCTR2005-002234-35-DE进行中（未招募）不适用
Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients - My Liver
ovartis Pharma GmbH0 个研究点开始时间: 2006年1月13日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.who received liver transplant at least 3 month prior to study enrollment;
- •2.receiving immunosuppressive regimen that includes a calcineurin or mTOR (tbd) inhibitor, steroids, and MMF at time of study enrollment;
- •3.receiving immunosuppressive therapy that includes MMF at a stable dose for at least 1 month prior to enrollment. Patients can only be enrolled into the study if it is expected that treatment will continue at the same dose until study end (6-8 weeks after enrollment);
- •4.with a medical condition that necessitates MPA-treatment for probably the next 6-8 weeks (time of study duration);
- •5.eligible and willing to convert to myfortic®;
- •6.stable on current immunosuppressive regimen;
- •7.at least 18 years of age;
- •8.willing to provide written informed consent;
- •9.able to meet all study requirements including completing the questionnaires and completing two study visits;
- •10.receiving drugs that may cause GI symptoms such as biphosphonates, minerals, vitamins, antibiotics or proton pump inhibitors (PPIs) have to be on a stable dose of these substances for at least 1 month prior to enrollment. Patients receiving these drugs can only be enrolled into the study, if it is expected that treatment will continue at the same dose until study end (6-8 weeks after enrollment).
- •11.Females capable of becoming pregnant must have a negative pregnancy test within 7 days prior to or at baseline. Pregnancy tests have to be repeated every 4 weeks. Females are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.If applicable, GI symptoms assumed or known not to be caused by MPA therapy (e.g. oral biphosphonates induced, infectious diarrhea);
- •2.Acute rejection < 1 week prior to study enrollment;
- •3.Women of child-bearing potential who are planning to become pregnant or are pregnant and/or lactating or who are unwilling to use effective means of contraception;
- •4.Presence of psychiatric illness (i.e., schizophrenia, major depression) that, in the opinion of the site investigator, would interfere with study requirements;
- •5.Undergoing acute medical intervention or hospitalization;
- •6.Presence of a medical condition not related to a GI event at time of visit, which requires immediate medical intervention;
- •7.Any other medical condition that, in the opinion of the site investigator based on recall or chart review, would interfere with completing the study, including but not limited to, visual problems or cognitive impairment;
- •8.Receiving any investigational drug or have received any investigational drug within 30 days prior to study enrollment.
- •9.Patients with hypersensitivity to mycophenolate sodium, mycophenolic acid, mycophenolic mofetil or other components of the formulation (e.g. lactose; see also SPCs).
研究者
相似试验
进行中（未招募）
不适用
Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Simultaneous Pancreas-Kidney Transplant Recipients - MyWayEUCTR2005-001144-23-DEovartis Pharma GmbH
进行中（未招募）
不适用
Measurement and Analysis of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Patients with Autoimmune Diseases treated with Mycophenolic Acid - MyGiantEUCTR2005-002233-12-DEovartis Pharma GmbH200
尚未招募
不适用
Evaluation of upper gastrointestinal tract surveillance in individuals with Lynch syndromeynch SyndromeDRKS00031932ationales Zentrum für erbliche Tumorerkrankungen, Universitätsklinikum Bonn5,000
已完成
不适用
on-invasive Measurements of Intestinal Failure-Associated Steatosis among adult patients.fatty liverNL-OMON45917Radboud Universitair Medisch Centrum60
已完成
不适用
InTerlaboratory Evaluation of a GastroIntestinal Activity ErgoMeterTest in Non-intense Trained PersOnsgastrointestinal activitygastrointestinal function10017947NL-OMON45536Hogeschool Utrecht16